Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | PPARD | Q03181 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27220662 | 0.86 | TRPV1 (0.55) | PPARGPPARAPPARDTRPV1EPHX2 | |
| SCHEMBL27188815 | 0.85 | ROCK2 (0.50) | PPARGPPARAPPARDROCK2ABL1 | |
| SCHEMBL29896178 | 0.85 | ROCK2 (0.50) | PPARGPPARAPPARDROCK2ABL1 | |
| SCHEMBL29896158 | 0.82 | POLB (0.47) | PPARGPPARAPPARDEPHX2ROCK2 | |
| SCHEMBL27188891 | 0.82 | POLB (0.47) | PPARGPPARAPPARDEPHX2ROCK2 | |
| SCHEMBL27188864 | 0.81 | EPHX2 (0.52) | PPARGPPARAPPARDTRPV1EPHX2 | |
| SCHEMBL29896128 | 0.81 | EPHX2 (0.52) | PPARGPPARAPPARDTRPV1EPHX2 | |
| SCHEMBL27188855 | 0.79 | PPARD (0.59) | PPARGPPARAPPARDEPHX2ROCK2 | |
| SCHEMBL29896181 | 0.79 | PPARD (0.59) | PPARGPPARAPPARDEPHX2ROCK2 | |
| SCHEMBL29538299 | 0.78 | PPARA (0.55) | PPARGPPARAPPARDTRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | claimed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | PPARG 3022/4885PPARA 2690/4885PPARD 2597/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | PPARG 3022/4885PPARA 2690/4885PPARD 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.